After being vindicated in her 2014 purchase of a U.S. company with a device to prop open diseased lungs, the chief executive of British healthcare group BTG (BTG.L) is scouring the horizon for the next promising acquisition.
BTG is best known for treating rattlesnake bites, with its antivenom drug CroFab, but Louise Makin sees a different future for the group as a hub for interventional medicine in which image-guided devices are used to treat a range of diseases.
Having delivered the first wave of such products for liver cancer, severe blood clots and varicose veins, Makin agreed her biggest acquisition last December by buying lung device firm PneumRx for $475 million.
